PDS Biotechnology Corporation (PDSB) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -78.24%, forward earnings yield 42.37%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.3 | -0.27 | 4.04 | 0.00 | - |
| 2017 | -5.6 | -0.23 | 4.57 | 0.00 | - |
| 2018 | 0.0 | 0.00 | 0.04 | 0.00 | - |
| 2019 | -1.8 | 0.02 | 1.10 | 0.00 | - |
| 2020 | -2.4 | 0.06 | 1.32 | 0.00 | - |
| 2021 | -12.3 | 0.47 | 3.28 | 0.00 | - |
| 2022 | -9.2 | -0.08 | 8.58 | 0.00 | - |
| 2023 | -3.6 | 1.28 | 5.89 | 0.00 | - |
| 2024 | -1.6 | 0.06 | 3.13 | 0.00 | - |
| 2025 | -1.0 | 0.03 | 3.86 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-26.90 | $0.00 | $-38.82M | - |
| 2017 | $-33.47 | $0.00 | $-50.86M | - |
| 2018 | $-26.16 | $0.00 | $-40.87M | - |
| 2019 | $-1.44 | $0.00 | $-7M | - |
| 2020 | $-0.89 | $0.00 | $-14.85M | - |
| 2021 | $-0.66 | $0.00 | $-16.92M | - |
| 2022 | $-1.43 | $0.00 | $-40.86M | - |
| 2023 | $-1.39 | $0.00 | $-42.94M | - |
| 2024 | $-1,079.45 | $0.00 | $-37.61M | - |
| 2025 | $-0.74 | $0.00 | $-36.84M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.67 | $-0.67 – $-0.67 | $11.25M | $11.25M – $11.25M | 2 |
| 2027 | $-0.69 | $-0.69 – $-0.69 | $23.15M | $23.15M – $23.15M | 2 |
| 2028 | $-0.67 | $-0.86 – $-0.48 | $3.8M | $3.8M – $3.8M | 2 |
| 2029 | $0.45 | $0.45 – $0.45 | $106.75M | $106.75M – $106.75M | 1 |
| 2030 | $1.47 | $1.47 – $1.47 | $196.92M | $196.92M – $196.92M | 1 |
